Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT326 in Advanced Solid Tumors
NCT07070232Phase 2Recruiting
- Sponsor
- BioNTech SE
- Start
- Aug 2025
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of YL202 in solid tumor, melanoma, non-small cell lung cancer (NSCLC), Cervical Cancer (CC), breast cancer, sponsored by BioNTech SE. Started Aug 2025; status: recruiting.
02
Drugs
YL202
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)Cervical Cancer (CC)breast cancer
Beyond the preview
Go deeper on NCT07070232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07070232.